JNJ

239.13

+0.39%↑

UNH

272.01

-0.45%↓

TMO

538.23

-4.32%↓

ABT

109.59

+0.95%↑

ISRG

486.71

+1.01%↑

JNJ

239.13

+0.39%↑

UNH

272.01

-0.45%↓

TMO

538.23

-4.32%↓

ABT

109.59

+0.95%↑

ISRG

486.71

+1.01%↑

JNJ

239.13

+0.39%↑

UNH

272.01

-0.45%↓

TMO

538.23

-4.32%↓

ABT

109.59

+0.95%↑

ISRG

486.71

+1.01%↑

JNJ

239.13

+0.39%↑

UNH

272.01

-0.45%↓

TMO

538.23

-4.32%↓

ABT

109.59

+0.95%↑

ISRG

486.71

+1.01%↑

JNJ

239.13

+0.39%↑

UNH

272.01

-0.45%↓

TMO

538.23

-4.32%↓

ABT

109.59

+0.95%↑

ISRG

486.71

+1.01%↑

Search

CareDx Inc

Abierto

SectorSalud

18.6 -3.23

Resumen

Variación precio

24h

Actual

Mínimo

18.18

Máximo

19.17

Métricas clave

By Trading Economics

Ingresos

10M

1.7M

Ventas

13M

100M

P/B

Media del Sector

15.953

84.243

Margen de beneficio

1.674

Empleados

644

EBITDA

11M

6.8M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 meses

-4.91% downside

Dividendos

By Dow Jones

Próximas Ganancias

25 feb 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

301M

1.1B

Apertura anterior

21.83

Cierre anterior

18.6

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

335 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

CareDx Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

5 feb 2026, 23:57 UTC

Ganancias

Naver Has Record Year Despite Weaker Final Quarter

5 feb 2026, 23:45 UTC

Acciones populares

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5 feb 2026, 22:26 UTC

Ganancias

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5 feb 2026, 22:00 UTC

Ganancias

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5 feb 2026, 23:47 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

5 feb 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5 feb 2026, 23:43 UTC

Charlas de Mercado

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5 feb 2026, 23:37 UTC

Charlas de Mercado

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5 feb 2026, 23:20 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5 feb 2026, 23:11 UTC

Charlas de Mercado

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5 feb 2026, 23:09 UTC

Ganancias

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5 feb 2026, 23:08 UTC

Ganancias

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5 feb 2026, 23:07 UTC

Ganancias

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5 feb 2026, 23:03 UTC

Charlas de Mercado
Ganancias

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5 feb 2026, 23:03 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5 feb 2026, 23:00 UTC

Ganancias

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5 feb 2026, 23:00 UTC

Ganancias

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5 feb 2026, 22:59 UTC

Ganancias

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5 feb 2026, 22:59 UTC

Ganancias

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5 feb 2026, 22:52 UTC

Ganancias

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5 feb 2026, 22:45 UTC

Ganancias

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5 feb 2026, 22:37 UTC

Charlas de Mercado

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5 feb 2026, 22:11 UTC

Ganancias

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5 feb 2026, 22:03 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5 feb 2026, 22:01 UTC

Ganancias

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5 feb 2026, 21:59 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5 feb 2026, 21:51 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5 feb 2026, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

5 feb 2026, 21:49 UTC

Ganancias

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5 feb 2026, 21:45 UTC

Ganancias

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Comparación entre iguales

Cambio de precio

CareDx Inc Esperado

Precio Objetivo

By TipRanks

-4.91% caída

Estimación a 12 meses

Media 18 USD  -4.91%

Máximo 18 USD

Mínimo 18 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

0

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

14.77 / 18.49Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

335 / 352 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
help-icon Live chat